{
  "docId": "019de072-50fd-76be-bc50-13d10a429187",
  "docSlug": "745181b5445c8f31a0d7e29e54da559e",
  "documentTitle": "Chimerix | Results Presentation Deck | 12 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 12,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes chemical structure of CMX521.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-50fd-76be-bc50-13d10a429187/5",
  "deckHref": "/decks/019de072-50fd-76be-bc50-13d10a429187",
  "deckJsonHref": "/decks/019de072-50fd-76be-bc50-13d10a429187.json",
  "deckAnchorHref": "/decks/019de072-50fd-76be-bc50-13d10a429187#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.675,
        "y": 0.575
      },
      "kind": "image",
      "text": "Chemical structure of CMX521",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "817fc25e-1c61-4c90-9954-b354f48b6221",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.65,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "list",
      "text": "CMX521 not mutagenic, clastogenic, cytotoxic or mitotoxic and demonstrated no significant off-target pharmacology; Oral formulation developed for norovirus disease; 7-day repeat dose LOAEL plasma exposures in dog > 10x human plasma exposure with 2.4 g oral dose; Phase 1 single ascending dose study in healthy volunteers (≤ 2400 mg; n = 38 subjects); Well-characterized metabolic and transporter interaction profile; Drug substance process robust and scalable to large kg scale batches",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f612c39d-c609-492b-8ab4-f8fbae494c5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.72,
        "x": 0.14,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Favorable safety profile in nonclinical species and humans with well-characterized nonclinical ADME profile",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db4de8a5-baff-4fc2-9ff0-6494027ac49f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.82,
        "x": 0.09,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oral CMX521 formulation developed through Phase 1 study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "509d6fa4-9888-4aeb-be9f-960a1fc4f2c8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "9687f69a-5694-4036-9e1a-accb2110ccf0",
      "evidence": "list/bullet: CMX521 not mutagenic, clastogenic, cytotoxic or mitotoxic",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}